5-tert-butyl-2-(3-chloro-4-methylphenyl)pyrazol-3-amine | 926242-93-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-tert-butyl-2-(3-chloro-4-methylphenyl)pyrazol-3-amine
• 英文别名: 3-tert-butyl-1-(3-chloro-4-methylphenyl)-1H-pyrazol-5-amine
• CAS: 926242-93-5
• 化学式: C₁₄H₁₈ClN₃
• mdl: MFCD08443231
• 分子量: 263.77
• InChiKey: OHZYEJIYUQWFGP-UHFFFAOYSA-N

物化性质

• 沸点：
  400.9±45.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-tert-butyl-2-(3-chloro-4-methylphenyl)pyrazol-3-amine 在 吡啶 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 36.0h， 生成 1-(3-(tert-butyl)-1-(3-chloro-4-methylphenyl)-1H-pyrazol-5-yl)-3-(2-(methylthio)-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea
  参考文献：
  名称：

  [EN] POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES
  [FR] DÉRIVÉS D'URÉE POLYAROMATIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES MUSCULAIRES

  摘要：

  当前的发明提供尿素衍生物，特别是具有核心结构杂环基-NH-CO-NH-芳基-O-杂环基的化合物，用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或症状，如杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症、虚弱或肌肉萎缩症。

  公开号：

  WO2021013712A1
• 作为产物：
  描述：

  新戊酰基乙腈 、 3-chloro-4-methylphenyl hydrazine hydrochloride 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以100%的产率得到5-tert-butyl-2-(3-chloro-4-methylphenyl)pyrazol-3-amine
  参考文献：
  名称：

  COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS

  摘要：

  本发明提供了一种与皮质类固醇或HDAC抑制剂联合使用的化合物，用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或病症，如杜氏肌萎缩症、贝克肌萎缩症、消瘦或肌肉萎缩症。

  公开号：

  EP4029501A1

文献信息

• Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases
  申请人：Butcher Kenneth John

  公开号：US20110003848A1

  公开（公告）日：2011-01-06

  The present invention relates to a polymorphic form B of Λ/[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl]-N-2-[(3-2-[(2-hydroxyethyl)sulfanyl]phenyl}[1,2,4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]benzyl}urea (I) as de-fined herein. This polymorph is useful in the treatment of various conditions, particularly in the treatment of inflammatory conditions such as chronic obstructive pulmonary disease.

  本发明涉及一种Λ/[3-叔丁基-1-(3-氯-4-羟基苯基)-1H-吡唑-5-基]-N-2-[(3-2-[(2-羟乙基)硫基]苯基}[1,2,4]三唑并[4,3-a]吡啶-6-基)硫基]苯基}脲（I）的多晶形式B，如本文所定义。这种多晶形式在治疗各种疾病中特别是治疗炎症性疾病如慢性阻塞性肺疾病方面有用。
• Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors
  作者：Jeffrey R. Simard、Matthäus Getlik、Christian Grütter、Vijaykumar Pawar、Sabine Wulfert、Matthias Rabiller、Daniel Rauh

  DOI：10.1021/ja902010p

  日期：2009.9.23

  Kinase disregulation disrupts the intricate network of intracellular signaling pathways and contributes to the onset of diseases such as cancer. Although several kinase inhibitors are on the market, inhibitor selectivity and drug resistance mutations persist as fundamental challenges in the development of effective long-term treatments. Chemical entities binding to less conserved allosteric sites would be expected to offer new opportunities for scaffold development. Because no high-throughput method was previously available, we developed a fluorescence-based kinase binding assay for identifying and characterizing ligands which stabilize the inactive kinase conformation. Here, we present a description of the development and validation of this assay using the serine/threonine kinase p38alpha. By covalently attaching fluorophores to the activation loop of the kinase, we were able to detect conformational changes and measure the K(d), k(on), and k(off) associated with the binding and dissociation of ligands to the allosteric pocket. We report the SAR of a synthesized focused library of pyrazolourea derivatives, a scaffold known to bind with high affinity to the allosteric pocket of p38alpha. Additionally, we used protein X-ray crystallography together with our assay to examine the binding and dissociation kinetics to characterize potent quinazoline- and quinoline-based type II inhibitors, which also utilize this binding pocket in p38alpha. Last, we identified the b-Raf inhibitor sorafenib as a potent low nanomolar inhibitor of p38alpha and used protein X-ray crystallography to confirm a unique binding mode to the inactive kinase conformation.
• US8222273B2
  申请人：——

  公开号：US8222273B2

  公开（公告）日：2012-07-17